Brief – Others 2026-10-04
Worth Noting
The Supreme Court takes up climate liability, with billions at stake for Big Oil. A Supreme Court Battle Over Climate Change Begins — the justices will decide whether oil companies can be sued in state court for damages tied to global warming, a case that could reshape corporate climate liability nationwide; notably, Justice Alito recused himself days before arguments over his oil-stock holdings.
The summer’s cyclospora outbreak traced to Mexican lettuce fields. F.D.A. Found Cyclospora During Taylor Farms Inspection in Mexico — inspectors found the parasite at a grower’s facility, adding hard evidence to an outbreak that sickened thousands, and raising fresh questions about oversight of imported produce.
Wildfire smoke carries a second, less-visible hazard: ozone. Scientists Warn of Another Unseen Risk From Fire: Ozone — new research finds ground-level ozone rising alongside the well-documented particulate danger from fires, a hazard regulators have largely overlooked.
A promising pancreatic cancer drug keeps failing the same way. Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working — researchers studying patients like former Senator Ben Sasse are probing why tumors inevitably develop resistance to daraxonrasib, insight that could shape the next generation of targeted therapies.
Geologists find Earth’s whole crust has rolled over repeatedly — and still is. Scientists discover that Earth’s crust has repeatedly rolled over—and it’s still happening — an analysis of ancient sea-level records suggests the solid planet itself periodically reorients, a striking revision to how we picture plate tectonics operating at the deepest scale.
A new weight-loss drug trial sets a higher bar than Ozempic or Zepbound. Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs — the triple-agonist drug reaching phase 3 posts standout results, a sign the obesity-drug arms race is far from over and will keep reshaping food, healthcare and restaurant economics.
One Thing Worth Reading Deeply
Dying Patients Are Inundated by Misinformation. My Dad Was One of Them. A reporter traces how her own father, dying of cancer, was drawn into a world of unproven alternative-medicine clinics that charge tens of thousands of dollars and thrive on online advertising and desperation. It’s a clear-eyed, personal account of how misinformation exploits terminal illness, and a sobering look at an industry operating largely outside regulatory scrutiny. Worth the full read for anyone who has watched a family member search for hope in the wrong places.